Christopher Hall Sells 19,909 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 19,909 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $11.02, for a total transaction of $219,397.18. Following the completion of the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $2,600,565.72. This trade represents a 7.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Up 3.8%

Shares of NASDAQ:PSNL opened at $11.40 on Friday. Personalis, Inc. has a 52-week low of $3.84 and a 52-week high of $11.85. The company has a 50 day moving average of $6.86 and a two-hundred day moving average of $8.10. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -11.18 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. On average, equities analysts anticipate that Personalis, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analyst Weigh In

PSNL has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC raised their price target on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Morgan Stanley decreased their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Finally, BTIG Research decreased their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Hedge Funds Weigh In On Personalis

Hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd boosted its holdings in Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the period. Legal & General Group Plc acquired a new position in Personalis in the second quarter worth $30,000. International Assets Investment Management LLC acquired a new position in Personalis in the fourth quarter worth $31,000. BNP Paribas Financial Markets boosted its holdings in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares during the period. Finally, Focus Partners Wealth acquired a new position in Personalis in the first quarter worth $47,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.